Verve Therapeutics Names Allison Dorval as Finance Chief
9:32AM ET on Monday Nov 29, 2021 by MT Newswires
09:32 AM EST, 11/29/2021 (MT Newswires) -- Verve Therapeutics (VERV) on Monday said that Allison Dorval has been named as chief financial officer. Dorval joins Verve from Voyager Therapeutics (VYGR), according to a statement. Price: 32.32, Change: -...
Verve Therapeutics Appoints Allison Dorval, Experienced Financial Executive, as Chief Financial Officer
8:08AM ET on Monday Nov 29, 2021 by GlobeNewswire
Verve Therapeutics, Inc., (Nasdaq: VERV), a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Allison Dorval has been appointed as chief financial officer. Ms. Dorval joins Verve from Voyager Therapeutics and brings more than 20 years of leadership experience in finance, accounting, financial reporting and investor relations.
BRIEF-Verve Therapeutics Appoints Allison Dorval As CFO
8:04AM ET on Monday Nov 29, 2021 by Thomson Reuters
Nov 29 (Reuters) - Verve Therapeutics Inc:
* VERVE THERAPEUTICS APPOINTS ALLISON DORVAL, EXPERIENCED
FINANCIAL EXECUTIVE, AS CHIEF FINANCIAL OFFICER
Verve Therapeutics' Q3 Net Loss Shrinks
7:51AM ET on Wednesday Nov 10, 2021 by MT Newswires
07:51 AM EST, 11/10/2021 (MT Newswires) -- Verve Therapeutics, Inc. (VERV) on Wednesday reported a Q3 net loss of $0.47 per share, compared with a loss of $3.81 per share in the year-earlier quarter. One analysts polled by Capital IQ expected a loss...